Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Mineralys reported new analyses from its Phase 3 Launch-HTN trial showing that 46% of lorundrostat-treated participants reached office systolic blood pressure <130 mmHg at 12 weeks and that 70% achieved ≥10 mmHg SBP reduction. Separate Phase 2 Explore-OSA results showed an 11.1 mmHg morning SBP reduction at Week 4 with lorundrostat 50 mg and no measurable change in apnea-hypopnea indices; the company reports no significant safety signals.